STTK(STTK)
STTK
ANALYST COVERAGE9 analysts
BUY
▲ +146.3%upside to target
L $11.00
Med $15.00consensus
H $18.00Key MetricsTTM
Market Cap$291.73M
Revenue TTM$1.00M
Net Income TTM-$49.87M
Free Cash Flow-$41.28M
Gross Margin-82.0%
Operating Margin-5266.4%
Net Margin-4987.4%
Return on Equity-60.7%
Return on Assets-48.8%
Debt / Equity0.02
Current Ratio22.06
EPS TTM$-0.44
PRICE
Prev Close
6.17
Open
6.10
Day Range5.92 – 6.14
5.92
6.14
52W Range0.71 – 8.33
0.71
8.33
71% of range
VOLUME & SIZE
Avg Volume
600.8K
FUNDAMENTALS
P/E Ratio
-10.9x
Not profitable
EPS (TTM)
—
Div Yield
No dividend
Beta
1.19
Market-like
TECHNICAL
RSI (14)
38
Bearish momentum
Upcoming Events
EEarnings Report
Tomorrow
May 23
DEx-Dividend
In 90 days
Aug 20
PDividend Pay
In 131 days
Sep 30
STTK News
About
Shattuck Labs, Inc. operates as a clinical-stage biotechnology company . The Company focuses on developing a novel class of biologic medicines for the treatment of cancer and autoimmune diseases. Shattuck Labs serves customers in the State of Texas.
Thomas LampkinSenior Vice President of Regulatory Affairs
Kelli CollinSenior Vice President of Quality
Abhinav A. ShuklaChief Technical Officer
Arundathy Nirmalini PanditeChief Medical Officer
Stephen StoutGeneral Counsel, Corporate Secretary and Chief Ethics & Compliance Officer
Taylor H. SchreiberCo-Founder, Chief Executive Officer & Director
Andrew R. NeillChief Financial Officer
Brad HuckabeeVice President of Accounting & SEC reporting
Suresh de SilvaChief Scientific Officer
Casi DeYoungChief Business Officer